Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2022-01-13 00:00:00 ET · period of report 2022-01-11 · accession 0001209191-22-003176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-13 | 2022-01-11 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $10.81 | +15.0K | 109.4K | +16% | +$162.2K |
| D | 2022-01-13 | 2022-01-11 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $0.00 | -15.0K | 58.7K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-11 | M | A | 15,000 | $10.81 | 109,374 | D | — | — | (F1) Includes 289 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-11 | M | D | 15,000 | $0.00 | 58,670 | D | $10.81 · — to 2022-06-05 | 15,000 Common Stock | (F3) The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. |